ROLE OF ESTROGENS IN HUMAN BENIGN PROSTATIC HYPERPLASIA

References

• Adlercreutz H, Hockerstedt K, Bannwart C, Bloigu S, Hamalainen E, Fotsis T, 011us A (1987): Effect of dietary components, including lignans and phytoestrogens, on enterohepatic circulation and liver metabolism of estrogens and on sex hormone binding globulin. J Steroid Biochem 27:1135–1144.
   Google Scholar
• Adlercreutz H, Honjo H, Higashi A, Fotsis T, Hamalainen E, Hasegawa T, Okada H (1991): Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a tradi-tional Japanese diet. Am J Clin Nutr 54:1093–1100.
   PubMed Web of Science ®Google Scholar
• Adlercreutz H, Markkanen H, Watanabe S (1993): Plasma concentrations of phytoestrogens in Japa-nese men. Lancet 342:1209–1210.
   PubMed Web of Science ®Google Scholar
• Baker NWG, Burger HG, DeKretser DM, Hudson B, O'Connor S, Wang C, Mirovics A, Court J, Dunlop M, Rennie GC (1976): Changes in the pituitary-testicular system with age. Clin Endocrinol 5:349–357.
   PubMed Web of Science ®Google Scholar
• Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984): The development of human benign prostatic hyperplasia with age. J Urol 132:474–479.
   Google Scholar
• Bhatnagar AS, Hausler A, Trunet P, Schieweck K, Lang M, Bowman P (1990): Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J Steroid Biochem Mol Biol 37:1021–1027.
   PubMed Web of Science ®Google Scholar
• Brodie AMH, Wing LY, Goss P, Dowsett M, Coombes RC (1986): Aromatase inhibitors and their potential clinical significance. J Steroid Biochem 25:859–865.
   Google Scholar
• Brodie AMH (1994): Aromatase inhibitors in the treatment of breast cancer. J Steroid Biochem Mol Biol 49:281–287.
   PubMed Web of Science ®Google Scholar
• Collins AT, Zhiming B, Gilmore K, Neal DE (1994): Androgen and oestrogen responsiveness of stromal cells derived from the human hyperplastic prostate: oestrogen regulation of the androgen receptors. J Endocrinol 143:269–277.
   PubMedGoogle Scholar
• Deslypere JP, Vermsulen A (1984): Leydig cell function in normal men: effect of age, life-style, residence, diet and activity. J Clin Endocrinol Metab 59:955–962.
   PubMed Web of Science ®Google Scholar
• Di Silverio F, Tenaglia R (1986): Anti-estrogens and anti-androgens in human benign prostatic hyper-plasia. In: Ipertrofia Prostatica Benigna. Di Silverio F, Neumann F, Tannenbaum M (Eds). Amsterdam: Excerpta Medica, pp 117–125.
   Google Scholar
• Ekman P, Barrack ER, Greene GL, Jensen EV, Walsh PC (1983): Estrogen receptors in human pros-tate: evidence for multiple binding sites. J Clin Endocrinol Metab 57:166–176.
   PubMed Web of Science ®Google Scholar
• Ekman P (1989): BPH epidemiology and risk factors. Prostate, Suppl 2:23–31.
   PubMedGoogle Scholar
• El Etreby MF, Habenicht UF (1994): The function and the role of aromatase inhibitors in the treat-ment of BPH. In: Benign Prostatic Hyperplasia. Kurt K, Newling DWW (Eds). New York: Wiley-Liss, pp 209–230.
   Google Scholar
• Geelen JAA, Loozen HJJ, Deckers GH, de Leeuw R, Kloosterboer HJ, Lamberts SWJ (1993): ORG 33201: a new highly selective orally active aromatase inhibitor. J Steroid Biochem Mol Biol 44:4–6.
   Google Scholar
• Geller J, Albert JD (1985): BPH and prostate cancer: results of hormonal manipulation. In: Regula-tion of Androgen Action. Bruchovsky N, Chapdelaine A, Neumann F (Eds). Berlin: Congressdruck R. Bruchner, pp 51–75.
   Google Scholar
• Gingell JC, Knonagel H, Kurth KH, Tunn UW (1995): Placebo controlled double-blind study to test the efficacy of the aromatase inhibitor atamestane in patients with benign prostatic hyperplasia not requiring operation. The Schering 90.062 Study Group. J Urol 154:399–401.
   Google Scholar
• Graham S, Haughey B, Marshall J (1983): Diet in the epidemiology of carcinoma of the prostate gland. JNCI 70:687–692.
   PubMed Web of Science ®Google Scholar
• Griffiths K, Coffey D, Cockett A, Ichikawa T, Lee C, Schalken J, Steiner G, Yamanaka H, di Sant'Agnese A, Krieg M, McKeehan W, Sciarra F, Sugimura Y (1995): The regulation of prostatic growth. 3rd Intern. Consultation on BPH, Principato di Monaco, S.C.I. Paris, pp 73–115.
   Google Scholar
• Griffiths K, Adlercreutz H, Boyle P, Denis L, Nicholson RI, Morton MS (1996): Nutrition and Can-cer. Oxford, UK: Isis Medical Media, pp 1–16.
   Google Scholar
• Hahn EF, Fishman J (1984): Immunological probe for estrogen biosynthesis: evidence for the 2f3-hydroxylative pathway in aromatization of androgens. J Biol Chem 259:1689–1694.
   PubMed Web of Science ®Google Scholar
• Haugen OA, Harbitz TB (1972): Prostatic weight in elderly men: an analysis in an autopsy series. Acta Pathol Microbiol Scand [A] 80:756–767.
   Google Scholar
• Henderson D, Habenicht UF, Nishino Y, Kerb U, El Etreby MF (1986): Aromatase inhibitors and benign prostatic hyperplasia. J Steroid Biochem 25:867–876.
   Google Scholar
• Henderson D, Habenicht UF, Nishino Y, El Etreby MF (1987): Estrogens and benign prostatic hyper-plasia: the basis of aromatase inhibitor therapy. Steroids 50:219–233.
   Google Scholar
• Horton R (1984): Benign prostatic hyperplasia a disorder of androgen metabolism in the male. Am J Geriatr 32:380–390.
   PubMed Web of Science ®Google Scholar
• Khan CR, Smith RJ, Chin WW (1998): Mechanism of action of hormones that act at the cell surphace. In: Williams Textbook of Endocrinology. Wilson JD, Foster DW (Eds). Philadelphia: Saunders, pp 95–134.
   Google Scholar
• Korach KS (1994): Insights from the study of animals lacking functional estrogen receptor. Science 266:1524–1527.
   PubMedGoogle Scholar
• Krieg M, Klotzl G, Kaufmann J, Voigt KD (1981): Stroma human benign prostatic hyperplasia: preferential tissue for androgen metabolism and estrogen binding. Acta Endocrinol (Copenh) 96:422–432.
   PubMedGoogle Scholar
• Krieg M, Bartsch W, Thomsen M, Voight KD (1982): Androgens and estrogens: their interaction with stroma and epithelium of human prostatic hyperplasia and normal prostate. J Steroid Biochem 5:155–161.
   Google Scholar
• Krieg M, Nass R, Tunn S (1993): Effect of aging on endogenous levels of 5a-dihydrotestosterone, testosterone, estradiol and estrone in epithelium and stroma of normal and hyperplastic human pros-tate. J Endocrinol 77:375–381.
   Google Scholar
• Kurzer MS, Xu X (1997): Dietary phytoestrogens. Annu Re Nutr 17:353–358.
   PubMed Web of Science ®Google Scholar
• Lipton A, Harvey HA, Demers LM, Hanagan JR, Mulaga M, Kochak GM, Fitzsimmons S, Snaders SI, Santen RJ (1990): A phase I trial of CGS 16949A: a new aromatase inhibitor. Cancer 65:1279–1286.
   PubMedGoogle Scholar
• Lubrano C, Sciarra F, Spera G, Petrangeli E, Toscano V, Rombolà N, Palleschi F, Palma E, Di Silverio F (1992): Immunoreactive EGF in human benign prostatic hyperplasia: relationships with androgen and estrogen receptors. J Steroid Biochem Mol Biol 41:683–687.
   PubMed Web of Science ®Google Scholar
• Mettlin C, Selenskas S, Natarajan N, Huben R (1986): Beta-carotene and animal fats and their rela-tionship to prostate cancer risk: a case control study. Cancer 53:817–821.
   Google Scholar
• Mills PK, Beeson WL, Phillips RL, Fraser GE (1989): Cohort study lifestyle and prostate cancer in Adventist men. Cancer 64:598–604.
   PubMed Web of Science ®Google Scholar
• Mont S, Di Silverio F, Toscano V, Martini C, Lanzara S, Varasano PA, Sciarra F(1998): Androgen concentrations and their receptors in the periurethral region are higher than those of the subcapsular zone in benign prostatic hyperplasia (BPH). J Androl 19:428–433.
   Google Scholar
• Nicholson RI, Davies P, Griffiths K (1978): Interaction of androgens with estradio1-17f3 receptor proteins in DMBA-induced mammary tumours: a possible oncolytic mechanism. Eur J Cancer 14:439–445.
   Google Scholar
• Radlmaier A, Eickenberg HU, Fletcher MS, Fourcade RO, Reis Santos JM, van Aubel OG, Bono AV (1996): Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group. Prostate 29:199–208.
   Google Scholar
• Schneider G, Kirschner MA, Ertel NH (1977): Increased serum estradiol in morbidly obese males. Endocrinology [Suppl 1], 100: 211–215.
   Google Scholar
• Schweikert HU, Tunn UW, Habenicht UF, Arnold J, Senge T, Schulze H, Schroder FH, Blom JH, Ennemoser O, Horniger W (1993): Effects of estrogen deprivation on human benign prostatic hyper-plasia. J Steroid Biochem Mole Biol 44:573–576.
   PubMed Web of Science ®Google Scholar
• Sciarra F, Concolino G, Tenaglia R, Di Silverio F (1988): Biochemical modifications in human be-nign prostatic hyperplasia (BPH). In: New Trends in BPH Etiopathogenesis, Di Silverio F, Steg A (Eds). Rome: Acta Medica, pp 277–282.
   Google Scholar
• Sciarra F (1991): Fattori ormonali nella etiopatogenesi dell'ipertrofia prostatica benigna. In: Ghiandole Endocrine e Invecchiamento, Andreani D, Motta M (Eds). Rome: Tipografia Poliglotta Vaticana, pp 195–206.
   Google Scholar
• Sciarra F (1995): Sex steroids and epidermal growth factor in benign prostatic hyperplasia. In: Ste-roid Receptors and Antihormones. Annals New York Acad Sci 761:66–78.
   PubMed Web of Science ®Google Scholar
• Sciarra F, Monti S, Trotta MC, Martini C, Tosti-Croce C, Toscano V (1995): Sistema riproduttivo maschile e invecchiamento. In: Atti Vifi Convegno Internazionale di Endocrinologia Medico-Chirurgica, Zarrilli L (Ed). Isola di Procida, pp 15–30.
   Google Scholar
• Severson RK, Nomura AMY, Grove JS, Stemmerman GN (1989): A prospective study of demograph-ics and prostate cancer among Japanese ancestry in Hawaii. Cancer Res 49:1857–1860.
   Google Scholar
• Snowdon DA, Philips RL, Choi W (1984): Diet, obesity and risk of fatal prostate cancer. Am J Epidemiol 120:244–250.
   PubMed Web of Science ®Google Scholar
• Talamini R, La Vecchia C, Decarli A (1986): Nutrition, social factors and prostatic cancer in a Northern Italian population. Br J Cancer 53:817–821.
   PubMed Web of Science ®Google Scholar
• Trunet PF, Mueller Ph, Bhatnagar AS, Dickes I, Monnet G, White G (1993): Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20267, in healthy male subjects. J Clin Endocrinol Metab 77:319–323.
   PubMed Web of Science ®Google Scholar
• Tunn UW, Kaivers P, Schweikert HU (1985): Conservative treatment of human benign prostatic hyperplasia. In: Regulation of Androgen Action, Bruchovsky N, Chapdelaine A, Neumann F (Eds). Berlin: Congressdruck R. Bruckner, pp 87–90.
   Google Scholar
• Tunn UW, Schweikert HU (1989): Aromatase inhibitors in the management of benign prostatic hy-perplasia. In: New Developments in Biosciences 5. Berlin: de Gruyter, pp 139–149.
   Google Scholar
• Vermeulen A, Rubens R, Verdonck L (1972): Testosterone secretion and metabolism in male senes-cence. J Clin Endocrinol Metab 34:730–739.
   Google Scholar
• Vermeulen A, De Sy (1976): Androgens in patients with benign prostatic hyperplasia before and after prostatectomy. J Clin Endocrinol Metab 43:1250–1254.
   PubMed Web of Science ®Google Scholar
• Voigt KD, Bartsch W (1986): Intratissular androgens in benign prostatic hyperplasia and prostate cancer. J Steroid Biochem 25:749–757.
   PubMedGoogle Scholar
• Von Schoultz B, Carlstrom K (1989): On the regulation of sex-hormone binding globulin: a challenge of an old dogma and outlines of an alternative mechanism. J Steroid Biochem 32:327–334.
   PubMedGoogle Scholar
• Walsh PC, Hutchins GM, Ewing LL (1983): Tissue content of dihydrotestosterone in human prostatic hyperplasia is not supranormal. J Clin Invest 72:1772–1781.
   Google Scholar
• Yatani R, Chigusa I, Akazaki K, Stemmerman GN, Welsh RA, Correa P (1982): Geographic pathol-ogy of latent prostatic cancer. Int J Cancer 29:611–616.
   PubMed Web of Science ®Google Scholar